Boron-Neutron Capture Therapy vs. Photon Beam for Malignant Brain Tumours — 12 Years’ Experience
Boron-Neutron Capture Therapy vs. Photon Beam for Malignant Brain Tumours — 12 Years’ Experience
复制标题
硼中子捕获疗法与光子束治疗恶性脑肿瘤 — 12 年经验
DOI：
10.1007/978-3-662-08801-2_15
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
K. Sano
中科院分区：
文献类型：
--
作者：
H. Hatanaka;K. Amano;S. Kamano;F. Tovaryš;N. Machiyama;T. Matsui;H. Fankhauser;T. Hanamura;T. Nukada;T. Kurihara;N. Ito;K. Sano
慢中子俘获疗法旨在用硼10、锂6和某些其他核素（6、9、16、19、34）的中子俘获反应产生的重粒子选择性地照射肿瘤组织。在 1953 年至 1961 年的早期试验中，对羧基苯基硼酸或全氢十硼酸钠 (29, 30)，以及最近自 1968 年以来的试验中，巯基十一氢十二硼酸盐已被用于脑肿瘤治疗 (8,28)。脑肿瘤最适合这种类型的治疗，因为所谓的血脑屏障现象允许将中子捕获同位素有区别地运输到肿瘤组织中，而不是运输到周围的脑物质中，从而在同位素浓度中产生很大的肿瘤/脑比率（1,4,20）。 1968年日本首次试验硼中子俘获疗法后，44例恶性脑肿瘤接受了中子俘获治疗。 44 人中的 32 人仅接受中子俘获治疗，但另外 12 人仅在之前的常规光子放疗失败后才接受治疗。将临床结果与 90 名接受光子治疗的患者进行了比较。大多数接受光子治疗的恶性神经胶质瘤患者都接受了化疗或免疫治疗药物的辅助治疗。排除采用常规放射治疗预后较好的肿瘤。
Slow neutron capture therapy is intended to irradiate tumor tissue selectively with heavy particles produced by the neutron-capturing reaction of Boron-10, Lithium-6 and certain other nuclides (6, 9, 16, 19, 34). In early trials between 1953 and 1961 p-carboxyphenyl boronic acid or sodium perhydrodecaborate (29, 30), and more recently, since 1968, mercaptoundecahydrododecaborate have been used for brain tumour treatment (8,28). Brain tumours are most suited to this type of therapy, because of the so-called Blood-Brain Barrier phenomenon which allows a discriminative transport of the neutron-capturing isotope into the tumour tissue but not into the surrounding brain matter, yielding a large Tumour/Brain ratio in isotope concentration (1, 4, 20). After the first trial of Boron-Neutron Capture Therapy in Japan in 1968, 44 malignant brain tumours were treated with neutron capture. Thirty-two of the 44 were treated with neutron capture alone, but 12 others were treated only after the failure of preceding conventional radiotherapy with photon. The clinical results were compared with that of 90 patients treated with photon. Most of the photon-treated patients with malignant gliomas underwent adjuvant therapy with chemo- or immuno-therapeutic agents. Tumours with better prognosis with conventional radiotherapy are excluded.